Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.31 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860359 | 1.00 | DGAT1 (0.31) | DGAT1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL25177119 | 0.87 | GRM2 (0.37) | DGAT1GRM2 | |
| SCHEMBL31210576 | 0.74 | GRM2 (0.35) | DGAT1GRM2 | |
| SCHEMBL24347955 | 0.67 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL1956444 | 0.67 | GRM2 (0.38) | GRM2 | |
| SCHEMBL1501700 | 0.66 | F2RL1 (0.34) | DGAT1 | |
| SCHEMBL31638938 | 0.66 | NPC1 (0.39) | DGAT1 | |
| SCHEMBL31056067 | 0.66 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL25165647 | 0.65 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL31056694 | 0.65 | DGAT1 (0.35) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140983-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230140983-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021174176-A9 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140983-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | DGAT1 3986/4885CSNK2A2 1430/4885CSNK2B 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.